Mody R, et al. - In this retrospective observational study, researchers assessed adherence [defined as a proportion of days covered ≥80%], persistence [measured by time to discontinuation of index therapy], glycaemic control and costs for patients initiating dulaglutide vs liraglutide or exenatide once a week at 12-month follow-up. Participants in the study were patients with type 2 diabetes (T2D) and ≥ 1 pharmacy claim for dulaglutide, liraglutide or exenatide once weekly from the HealthCore Integrated Research Database. Change from baseline to concentration of glycated haemoglobin (HbA1c) with pre- and post-index HbA1c results were evaluated in a subset. Investigators found that adherence and persistence for patients with T2D are important considerations in patient-centric treatment selection. For patients with T2D, higher adherence and persistence for dulaglutide vs liraglutide or exenatide once a week are relevant criteria when choosing glucagon-like peptide-1 receptor agonist treatment. The total cost of diabetes was not significantly different between the dulaglutide and the liraglutide group ($16,174 vs $16,694) and was significantly higher once a week for dulaglutide vs exenatide ($15,768 vs $14,615).